<DOC>
	<DOCNO>NCT02914275</DOCNO>
	<brief_summary>This study ass immune ( antibody ) response safety Seqirus split virion , inactivated Quadrivalent Influenza Vaccine ( Seqirus QIV ) , comparison US license 2016/2017 Quadrivalent Influenza Vaccine ( comparator QIV ) healthy pediatric population 6 month 59 month age .</brief_summary>
	<brief_title>A Study Evaluate Immunogenicity Safety Seqirus Quadrivalent Influenza Vaccine ( QIV ) Pediatric Population 6 Months Through 59 Months Age .</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject 6 month 59 month age time first vaccination bear 36 42 week gestation ; Parent legally acceptable representative able provide write informed consent willing able adhere protocol requirement include blood draw . Subject generally good health per Investigator 's medical judgment History allergic reaction egg proteins component Study Vaccines ; History serious adverse reaction influenza vaccine ; History GuillainBarré syndrome demyelinate disease encephalomyelitis transverse myelitis ; History license investigational influenza vaccination last 6 month ; Clinical sign active infection and/or axillary temperature ≥ 99.5°F / ( ≥ 37.5 °C ) day vaccination within 48 hour precede vaccination . Current recent , acute chronic medical condition opinion Investigator clinically significant and/or unstable *History seizure , exception single febrile seizure ; Selfreported know seropositivity suggestive acute chronic viral infection human immunodeficiency virus , hepatitis B hepatitis C ; Known suspect congenital acquire immunosuppressive condition ; Current recent immunosuppressive immunomodulatory therapy Current medical history malignant neoplasm ; Administration immunoglobulin and/or blood product within previous 90 day precede administration Study Vaccine plan administration study ; Participation clinical trial use investigational compound within 28 day prior 28 day receive Study Vaccine , plan enter study period ; Vaccination license vaccine 21 day ( live inactivate vaccine ) prior receive Study Vaccine , plan receive license vaccine prior Study Exit Visit .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>